Dayan CM, Lecumberri B, Muller I, et al. Endocrine and multiple sclerosis outcomes in patients with autoimmune thyroid events in the alemtuzumab CARE-MS studies. Multiple Sclerosis Journal - Experimental, Translational and Clinical. 2023;9(1).

Ghiani, M.; Zhuleku, E.; Dillenseger, A.; Maywald, U.; Fuchs, A.; Wilke, T.; Ziemssen, T. Data Resource Profile: The Multiple Sclerosis Documentation System 3D and AOK PLUS Linked Database (MSDS-AOK PLUS). J. Clin. Med. 2023, 12, 1441.

Callegari I, Schneider M, Aebischer V, Voortman MM, Proschmann U, Ziemssen T, Lindberg R, Fischer-Barnicol B, Khalil M, Kappos L, Kuhle J, Sanderson NSR, Derfuss T. Natalizumab in cerebrospinal fluid and breastmilk of patients with multiple sclerosis. Ther Adv Neurol Disord. 2023 Jan 30;16:17562864221150040.

Masanneck L, Räuber S, Schroeter CB, Lehnerer S, Ziemssen T, et al. Driving time-based identification of gaps in specialised care coverage: An example of neuroinflammatory diseases in Germany. DIGITAL HEALTH. 2023;9.

Orschiedt J, Jacyshyn-Owen E, Kahn M, Jansen S, Joschko N, Eberl M, Schneeweiss S, Friedrich B, Ziemssen T. The influence of the COVID-19 pandemic on the prescription of multiple sclerosis medication in Germany. Biomed Pharmacother. 2023 Feb;158:114129.

Shinoda K, Li R, Rezk A, Mexhitaj I, Patterson KR, Kakara M, Zuroff L, Bennett JL, von Büdingen HC, Carruthers R, Edwards KR, Fallis R, Giacomini PS, Greenberg BM, Hafler DA, Ionete C, Kaunzner UW, Lock CB, Longbrake EE, Pardo G, Piehl F, Weber MS, Ziemssen T, Jacobs D, Gelfand JM, Cross AH, Cameron B, Musch B, Winger RC, Jia X, Harp CT, Herman A, ...

Ziemssen T, Bhan V, Chataway J, Chitnis T, Campbell Cree BA, Havrdova EK, et al. Secondary Progressive Multiple Sclerosis: A Review of Clinical Characteristics, Definition, Prognostic Tools, and Disease-Modifying Therapies. Neurol Neuroimmunol Neuroinflamm 2023;10(1).

Ziemssen T, Groth M, Ettle B, Bopp T. Immune Response to SARS-CoV-2 mRNA Vaccines in an Open-Label Multicenter Study in Participants with Relapsing Multiple Sclerosis Treated with Ofatumumab. Vaccines (Basel). 2022 Dec 16;10(12):2167.